AngioDynamics, Inc. (NASDAQ:ANGO)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $21.60 and last traded at $20.93, with a volume of 2027 shares trading hands. The stock had previously closed at $21.13.
A number of equities analysts have issued reports on ANGO shares. Canaccord Genuity increased their price objective on AngioDynamics from $14.00 to $18.00 and gave the stock a “hold” rating in a report on Friday, January 8th. Raymond James increased their price objective on AngioDynamics from $18.00 to $24.00 and gave the stock a “strong-buy” rating in a report on Friday, January 8th. Finally, Zacks Investment Research downgraded AngioDynamics from a “buy” rating to a “hold” rating and set a $15.00 price objective for the company. in a report on Tuesday, December 1st.
The business has a fifty day simple moving average of $17.80 and a 200-day simple moving average of $12.79. The company has a quick ratio of 2.19, a current ratio of 3.27 and a debt-to-equity ratio of 0.09. The firm has a market cap of $819.26 million, a P/E ratio of -4.83 and a beta of 0.89.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 6th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. AngioDynamics had a negative return on equity of 0.12% and a negative net margin of 62.82%. The firm had revenue of $72.80 million during the quarter, compared to the consensus estimate of $67.33 million. During the same period last year, the company earned $0.06 earnings per share. The company’s revenue was up 4.0% on a year-over-year basis. On average, sell-side analysts anticipate that AngioDynamics, Inc. will post 0.01 EPS for the current fiscal year.
In other news, Director Wesley Johnson sold 6,500 shares of the firm’s stock in a transaction on Wednesday, January 20th. The stock was sold at an average price of $18.53, for a total transaction of $120,445.00. Following the completion of the transaction, the director now directly owns 77,911 shares in the company, valued at $1,443,690.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of ANGO. Bank of America Corp DE increased its holdings in shares of AngioDynamics by 54.6% during the second quarter. Bank of America Corp DE now owns 59,611 shares of the medical instruments supplier’s stock valued at $606,000 after acquiring an additional 21,043 shares in the last quarter. 6 Meridian boosted its position in shares of AngioDynamics by 10.1% during the third quarter. 6 Meridian now owns 11,692 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 1,071 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of AngioDynamics by 71.6% during the third quarter. Louisiana State Employees Retirement System now owns 17,500 shares of the medical instruments supplier’s stock valued at $211,000 after buying an additional 7,300 shares during the last quarter. Paradigm Capital Management Inc. NY purchased a new stake in shares of AngioDynamics during the third quarter valued at $1,580,000. Finally, State of New Jersey Common Pension Fund D boosted its position in shares of AngioDynamics by 33.9% during the third quarter. State of New Jersey Common Pension Fund D now owns 243,256 shares of the medical instruments supplier’s stock valued at $2,934,000 after buying an additional 61,602 shares during the last quarter. Hedge funds and other institutional investors own 94.86% of the company’s stock.
About AngioDynamics (NASDAQ:ANGO)
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.
Featured Article: Shanghai Stock Exchange Composite Index
Receive News & Ratings for AngioDynamics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AngioDynamics and related companies with MarketBeat.com’s FREE daily email newsletter.